BioArctic
BioArctic: Outlicenses PyroGlutamate-amyloid-beta antibody program to BMS (Redeye)
2024-12-19 08:59
Redeye endorses the news that BioArctic has signed a licensing agreement with BMS regarding BioArctic's PyroGlutamate-amyloid-beta antibody program and give our initial take.
info@redeye.se (Redeye.se)
Redeye AB - Redeye.se